07.24.24 -- Outsourcing At Cerus: Blood, Sweat … And FTEs?

Discover CASP technologies - the award-winning AI and vast data that propel Lonza’s leading predictive retrosynthesis technology, used to mitigate the impact of rising small mol API complexity and its resulting longer syntheses. Learn how it’s been tailored for Preclinical Route Design, and impacted synthetic route brevity, supply chain strategy and route selection as part of their Lonza AI-Enabled Route Scouting Service. Click here.

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

Discover how to construct an agreement between partners that favors fluid communication and alignment of business objectives — crucial for a fruitful CDMO relationship to diminish risk for both.

As molecular complexity continues to increase, flow chemistry is becoming an essential technology to facilitate the integration of complex synthetic methods into API production.

Explore the application of in vitro flux assays to nanoparticles, with data on how the in vitro permeability apparatus can characterize the membrane flux performance of an API formulated as a nanosuspension.

Nanomilling is emerging as an innovative technology designed to overcome solubility challenges and enhance bioavailability. Acquire invaluable knowledge and discover effective solutions to address your API challenges promptly.

Spray drying of amorphous dispersions improves solubility and bioavailability that enables supersaturation, driving higher rates of absorption when compared to crystalline drug forms.

What's your development and manufacturing outsourcing strategy based on? Do you have the right contracts and external relationships in place to successfully implement that strategy? Are there new models for sponsor-CDMO partnerships? Join Outsourced Pharma Live on August 13th as our panel of professionals will provide personal analysis and ideas for determining how you might best conduct your development and manufacturing activities, outsourcing business models, and external relationships.

We have defined workflows to assess and select solid forms in a cost and time efficient manner that meets the needs of each individual program.

For poorly soluble drugs, overcoming absorption hurdles can hinder development. KinetiSol™ Technology empowers researchers to overcome solubility limitations and accelerate timelines.